176 related articles for article (PubMed ID: 15298487)
1. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
Ayyoub M; Taub RN; Keohan ML; Hesdorffer M; Metthez G; Memeo L; Mansukhani M; Hibshoosh H; Hesdorffer CS; Valmori D
Cancer Immun; 2004 Aug; 4():7. PubMed ID: 15298487
[TBL] [Abstract][Full Text] [Related]
2. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
3. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
6. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Dubovsky JA; McNeel DG
Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
[TBL] [Abstract][Full Text] [Related]
7. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
9. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
10. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.
Calabrò L; Fonsatti E; Altomonte M; Pezzani L; Colizzi F; Nanni P; Gattei V; Sigalotti L; Maio M
J Cell Physiol; 2005 Feb; 202(2):474-7. PubMed ID: 15389591
[TBL] [Abstract][Full Text] [Related]
11. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
12. SSX antigens as tumor vaccine targets in human sarcoma.
Ayyoub M; Brehm M; Metthez G; Talbot S; Dutoit V; Taub RN; Keohan ML; Gure AO; Chen YT; Williamson B; Jungbluth AA; Old LJ; Hesdorffer CS; Valmori D
Cancer Immun; 2003 Oct; 3():13. PubMed ID: 14533943
[TBL] [Abstract][Full Text] [Related]
13. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
14. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
16. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
17. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
19. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
20. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
